Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pituitary Neoplasm: early-phase trial registry
1 of 3 indexed Pituitary Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Pituitary Neoplasm: 3 US clinical trials tracked, 1 recruiting.
Pituitary Neoplasm is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Neurological Disorders and Stroke (NINDS), running 2 of these trials.
Enrollment posture brief
Registry condition pituitary-neoplasm
OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Pituitary Neoplasm lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pituitary Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pituitary Neoplasm is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery
National Institute of Neurological Disorders and Stroke (NINDS)
NCT03678389
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
National Institute of Neurological Disorders and Stroke (NINDS)
NCT01459237
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00001860
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pituitary Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pituitary Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pituitary Neoplasm page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Pituitary Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Neurological Disorders and Stroke (NINDS) sponsors the most Pituitary Neoplasm trials on record, review their full trial history before evaluating a specific study. See National Institute of Neurological Disorders and Stroke (NINDS)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pituitary Neoplasm condition card totals 3 registered trials; most-linked intervention Sandostatin LAR Depot versus transsphenoidal surgery; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.